A new study presented recently at the American Society of Clinical Oncology conference in Chicago concluded that a new breathalyzer using a NaNose nanotech chip may accurately detect lung cancer and identify the stage of progression. The breath analyzer is based upon the knowledge that lung cancer tumors produce chemicals called volatile organic compounds (VOC) that easily evaporate into air and produce a discernible scent. The study included 358 patients who were either diagnosed with or at risk for lung cancer. The device accurately distinguished healthy people from those with early stage lung cancer 85 percent of the time, and healthy people from those with advanced stage lung cancer 82 percent of the time. The test also accurately distinguished those with early from late stage lung cancer 79 percent of the time. The researchers hope the test will allow lung cancer patients to be diagnosed with a non-invasive procedure and a Boston Based company, Alpha Szenszor, has licensed the technology and plans to introduce it to the market within the next few years.
Search by Illness or Therapy
changes in prevention and treatment follow. We have checked the sources believed to be reliable in an effort to provide information that is complex, accurate and reliable on this website. However, in view of the possibility of human error or changes in research findings neither the Board of Directors nor any other party who have been involved in the development of this website is responsible for any errors or omissions or the results obtained from the use of such information. Visitors are encouraged to confirm the information contained herein with other sources.
© 2014 to 2017. Carl O. Helvie Holistic Cancer Foundation. All Rights Reserved.